metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population
versus Standard of Care (SoC)
	durvalumab plus tremelimumab
	MYSTIC (DT ; all population), 2020 JAMA Oncol 2020 May 1;6(5):661-674. NCT02453282	RCT	mNSCLC - L1 - all population	durvalumab and tremelimumab	platinum-based doublet chemotherapy	first-line treatment of patients locally advanced or metastatic NSCLC with PDL1 TC >=25%	372 / 372	some concern	inconclusive
	nivolumab plus ipilimumab plus SoC
	CheckMate 9LA, 2021 Lancet Oncol 2021 Jan 18;S1470-2045(20)30641-0. ESMO Open. 2021 Oct 1 NCT03215706	RCT	mNSCLC - L1 - all population	nivo plus ipi and chemo (2 cycle)	chemotherapy platine combination	patient treated as First Line Therapy in squamous or non-squamous stage IV or recurrentNSCLC	361 / 358	some concern	conclusif